Sienna Biopharmaceuticals’ (NASDAQ:SNNA) lock-up period will end on Tuesday, January 23rd. Sienna Biopharmaceuticals had issued 4,333,333 shares in its IPO on July 27th. The total size of the offering was $64,999,995 based on an initial share price of $15.00. After the end of the company’s lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Separately, Guggenheim started coverage on Sienna Biopharmaceuticals in a report on Tuesday, December 5th. They issued a “neutral” rating and a $21.00 price objective for the company.
Shares of Sienna Biopharmaceuticals (NASDAQ SNNA) opened at $18.81 on Thursday. Sienna Biopharmaceuticals has a twelve month low of $15.22 and a twelve month high of $29.25.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in Sienna Biopharmaceuticals in the 3rd quarter worth about $1,133,000. California State Teachers Retirement System bought a new stake in Sienna Biopharmaceuticals in the 3rd quarter worth about $182,000. Citadel Advisors LLC bought a new stake in Sienna Biopharmaceuticals in the 3rd quarter worth about $440,000. TimesSquare Capital Management LLC bought a new stake in shares of Sienna Biopharmaceuticals during the 3rd quarter valued at about $8,571,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Sienna Biopharmaceuticals during the 3rd quarter valued at about $274,000. Institutional investors own 39.29% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Sienna Biopharmaceuticals Inc’s Lock-Up Period Set To Expire on January 23rd (NASDAQ:SNNA)” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3143350/sienna-biopharmaceuticals-incs-lock-up-period-set-to-expire-on-january-23rd-nasdaqsnna.html.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.